Interleukin 2 immune response generating formulation, used for treating cancer, comprises IL 2 coupled to transport protein, monoclonal anti IL 2 antibody or monoclonal anti CD 25 antibody

NOVELTY - A formulation comprising one or more components chosen from interleukin (IL)-2 or a derivative thereof coupled to a transport protein, a monoclonal anti-IL-2 antibody, a cancer vaccine based on specific antigens of tumors or tumor growth factors or a monoclonal anti-CD25 antibody, is new. USE - The formulations are used to produce drugs for inducing an anti-IL-2 immune response capable of inhibiting the growth of tumors in cancer patients (claimed). ADVANTAGE - Auto-antibodies which block binding of IL-2 to its receptor are induced and inhibit tumor growth. DETAILED DESCRIPTION - A therapeutic formulation capable of generating an immune response to Interleukin 2 (IL-2), used for treating cancer patients, comprises at least one component chosen from: (a) IL-2 or a derivative thereof coupled to a transport protein genetically or by chemical bonding, as well as a suitable adjuvant; (b) a monoclonal anti-IL-2 antibody; (c) a cancer vaccine based on specific antigens of tumors or tumor growth factors; or (d) a monoclonal anti-CD25 antibody.